 |
 Video: What is a Stock Split?
|
|
|
| Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor. According to our Zentalis Pharmaceuticals stock split history records, Zentalis Pharmaceuticals has had 0 splits. | |
|
Zentalis Pharmaceuticals (ZNTL) has 0 splits in our Zentalis Pharmaceuticals stock split history database.
Looking at the Zentalis Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Zentalis Pharmaceuticals shares, starting with a $10,000 purchase of ZNTL, presented on a split-history-adjusted basis factoring in the complete Zentalis Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/06/2020 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$24.39 |
|
| End price/share: |
$11.77 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-51.74% |
|
| Average Annual Total Return: |
-16.46% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$4,825.16 |
|
| Years: |
4.05 |
|
|
|
|
|
